Alveolar echinococcosis
A number of strategies are geared towards prevention and control of alveolar echinococcosis—most of which are similar to those for cystic echinococcosis. For instance, health education programs, improved water sanitation, improved hygiene and de-worming of hosts (particularly red foxes) are all effective to prevent and control the spread of alveolar echinococcosis. Unlike cystic echinococcosis, however, where there is a vaccine against E. granulosus, there is currently no canidae or livestock vaccine against E. multilocularis. Polycystic echinococcosis
While a number of control and prevention strategies deal with cystic and alveolar echinococcosis, there are few methods to control and prevent polycystic echinococcosis. This is probably due to the fact that polycystic echinococcosis is restricted to Central and South America, and that the way that humans become accidental hosts of E. oligarthrus and E. vogeli is still not completely understood. Human vaccines
Currently there are no human vaccines against any form of echinococcosis. However, there are studies being conducted that are looking at possible vaccine candidates for an effective human vaccine against echinococcosis. Treatment
Cystic
A number of therapy options are presently available. Treatment with albendazole, whether combined or not with praziquantel, is useful for smaller, uncomplicated cysts (< 5 cm). Only 30% of cysts disappear with medical treatment alone. Noramlly, albendazole is preferred twice a day for 1–5 months. An alternative to albendazole is mebendazole for at least 3 to 6 months. Surgery is indicated for bigger liver cysts (> 10 cm), and cysts at risk of rupture and/or complicated cysts.
multilocularis mainly occurs in the Northern hemisphere, including central Europe and the northern parts of Europe, Asia, and North America. However, its distribution was not always like this. For instance, until the end of the 1980s, E. multilocularis endemic areas in Europe were known to exist only in France, Switzerland, Germany, and Austria. But during the 1990s and early 2000s, there was a shift in the distribution of E. multilocularis as the infection rate of foxes escalated in certain parts of France and Germany.As a result, several new endemic areas were found in Switzerland, Germany, and Austria and surrounding countries such as the Netherlands, Belgium, Luxembourg, Poland, the Czech Republic, the Slovak Republic, and Italy. There is also evidence showing that the Baltic Countries are endemic areas.While alveolar echinococcosis is not extremely common, it is believed that in the coming years it will be an emerging or re-emerging disease in certain countries as a result of E. multilocularis’ ability to spread.Unlike the previous two species of Echinococcus, E. vogeli and E. oligarthrus are limited to Central and South America. Furthermore, infections by E. vogeli and E. oligarthrus (polycystic echinococcosis) are considered to be the rarest form of echinococcosis. Deaths
As of 2010 it caused about 1200 deaths, down from 2000 in 1990. History
Echinococcosis is a disease that has been recognized by humans for centuries. There has been mention of it in the Talmud. It was also recognized by ancient scholars such as Hippocrates, Aretaeus, Galen and Rhazes.